This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Banach-Petrosky, W. Articles by Abate-Shen, C. Search for Related Content PubMed PubMed Citation Articles by Banach-Petrosky, W. Articles by Abate-Shen, C.

Prolonged Exposure to Reduced Levels of Androgen Accelerates Prostate Cancer Progression in Nkx3.1; Pten Mutant Mice

¹ Center for Advanced Biotechnology and Medicine and ² Department of Medicine, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, Piscataway, New Jersey and ³ Department of Biomedical Informatics, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio

Requests for reprints: Cory Abate-Shen, Columbia University College of Physicians and Surgeons, Herbert Irving Comprehensive Cancer Center, 1130 St. Nicholas Ave., Room 217A, New York, NY 10032. Phone: 212-851-4731; E-mail: ca2319{at}columbia.edu.

In this report, we have investigated the relationship between androgen levels and prostate tumorigenesis in Nkx3.1; Pten mutant mice, a genetically engineered mouse model of human prostate cancer. By experimentally manipulating serum levels of testosterone in these mice for an extended period (i.e., 7 months), we have found that prolonged exposure of Nkx3.1; Pten mutant mice to androgen levels that are 10-fold lower than normal (the "Low-T" group) resulted in a marked acceleration of prostate tumorigenesis compared with those exposed to androgen levels within the reference range (the "Normal-T" group). We found that prostate tumors from the Low-T mutant mice share a similar gene expression profile as androgen-independent prostate tumors from these mutant mice, which includes the deregulated expression of several genes that are up-regulated in human hormone-refractory prostate cancer, such as Vav3 and Runx1. We propose that exposure to reduced androgens may promote prostate tumorigenesis by selecting for molecular events that promote more aggressive, hormone-refractory tumors. [Cancer Res 2007;67(19):9089–96]

This article has been cited by other articles:

				G. L. Lu-Yao, P. C. Albertsen, D. F. Moore, W. Shih, Y. Lin, R. S. DiPaola, and S.-L. Yao Survival Following Primary Androgen Deprivation Therapy Among Men With Localized Prostate Cancer JAMA, July 9, 2008; 300(2): 173 - 181. [Abstract] [Full Text] [PDF]

				L. S. Lyons, S. Rao, W. Balkan, J. Faysal, C. A. Maiorino, and K. L. Burnstein Ligand-Independent Activation of Androgen Receptors by Rho GTPase Signaling in Prostate Cancer Mol. Endocrinol., March 1, 2008; 22(3): 597 - 608. [Abstract] [Full Text] [PDF]